OCUL
NEUTRAL
$8.91
Live
Ocular Therapeutix, Inc. · NASDAQ
Target $26.0
(+191.8%)
$6.23
52W Range
$16.44
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$1.94B
P/E
N/A
ROE
-54.9%
Profit margin
N/A
Debt/Equity
0.12
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
OCUL presents a stark dichotomy between financial stability and operational performance, anchored by a stable Piotroski F-Score of 6/9. While the company maintains a fortress-like balance sheet with an exceptional current ratio of 15.39 and minimal debt, it is struggling with negative revenue growth (-22.4% YoY) and severe margin compression. The valuation is extremely aggressive with a Price/Sales ratio of 37.34, which is difficult to justify given the current earnings trajectory. Despite a 'Strong Buy' analyst consensus and a high target price of $26.00, bearish insider activity and a 0/100 technical trend suggest significant near-term headwinds.
Key Strengths
Exceptional liquidity with a current ratio of 15.39
Very low leverage (Debt/Equity of 0.12)
Stable financial trend as indicated by a Piotroski F-Score of 6/9
Strong analyst conviction with a target price of $26.00
Recent Q/Q EPS improvement (+23.7% growth in loss narrowing)
Key Risks
Severe revenue contraction (-22.4% YoY and Q/Q)
Extreme valuation premium (P/S ratio of 37.34)
Negative gross and operating margins indicating high burn/inefficiency
Consistent history of missing earnings estimates (1/4 beats in last year)
Bearish insider sentiment with multiple officer sales
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
35
Weak
15
35
40
85
0
AI Verdict
Speculative Hold
Key drivers: Balance sheet strength, Revenue decline, Extreme P/S valuation, Insider selling
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book is moderate at 2.94
Watchpoints
- P/S ratio of 37.34 is unsustainable for shrinking revenue
- Negative Forward P/E
- No Graham Number available due to lack of earnings
Future
35/100
Ref Growth rates
Positives
- High analyst target price suggests pipeline potential
Watchpoints
- Negative YoY and Q/Q revenue growth
- Consistent EPS misses
Past
40/100
Ref Historical trends
Positives
- 1Y return of +18.3%
Watchpoints
- 5Y change is -43.9%
- Poor earnings surprise track record
Health
85/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 6/9
- Current Ratio 15.39
- Debt/Equity 0.12
Watchpoints
- Negative ROE and ROA
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$8.91
Analyst Target
$26.0
Upside/Downside
+191.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OCUL and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OCUL
Ocular Therapeutix, Inc.
Primary
|
-43.9% | +53.6% | +18.3% | -25.4% | +3.2% | +5.8% |
|
ATRC
AtriCure, Inc.
Peer
|
-33.0% | -7.6% | -3.2% | +24.0% | -3.6% | +0.0% |
|
MESO
Mesoblast Limited
Peer
|
-15.5% | +113.7% | +36.9% | -19.0% | +1.0% | -1.1% |
|
GLPG
Galapagos NV
Peer
|
-63.1% | -24.7% | +17.3% | -16.1% | -14.0% | -2.9% |
|
AUPH
Aurinia Pharmaceuticals Inc.
Peer
|
-22.4% | +77.0% | +81.0% | +62.7% | -10.7% | -2.1% |
OCU
Ocular Therapeutix, Inc.
Primary
5Y
-43.9%
3Y
+53.6%
1Y
+18.3%
6M
-25.4%
1M
+3.2%
1W
+5.8%
ATR
AtriCure, Inc.
Peer
5Y
-33.0%
3Y
-7.6%
1Y
-3.2%
6M
+24.0%
1M
-3.6%
1W
+0.0%
MES
Mesoblast Limited
Peer
5Y
-15.5%
3Y
+113.7%
1Y
+36.9%
6M
-19.0%
1M
+1.0%
1W
-1.1%
GLP
Galapagos NV
Peer
5Y
-63.1%
3Y
-24.7%
1Y
+17.3%
6M
-16.1%
1M
-14.0%
1W
-2.9%
AUP
Aurinia Pharmaceuticals Inc.
Peer
5Y
-22.4%
3Y
+77.0%
1Y
+81.0%
6M
+62.7%
1M
-10.7%
1W
-2.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-7.09
PEG Ratio
N/A
P/B Ratio
2.94
P/S Ratio
37.34
EV/Revenue
24.63
EV/EBITDA
-4.82
Market Cap
$1.94B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-526.49%
Gross Margin
-292.04%
ROE
-54.85%
ROA
-26.66%
Growth
Revenue and earnings growth rates
Revenue Growth
-22.4%
Earnings Growth
N/A
Q/Q Revenue Growth
-22.43%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.12
Low debt
Current Ratio
15.39
Strong
Quick Ratio
15.11
Excellent
Cash/Share
$3.39
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
88.0%
Op. Margin
-526.5%
Net Margin
-488.0%
Total Assets
$0.8B
Liabilities
$0.2B
Equity
$0.7B
Debt/Equity
0.23x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
105%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-05
$-0.29
+13.9% surprise
2025-11-04
$-0.38
-9.6% surprise
2025-08-05
$-0.39
-10.7% surprise
Healthcare Sector Comparison
Comparing OCUL against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-54.85%
This Stock
vs
-100.15%
Sector Avg
-45.2%
(Below Avg)
Debt to Equity
0.12
This Stock
vs
3.22
Sector Avg
-96.3%
(Less Debt)
Revenue Growth
-22.4%
This Stock
vs
121.05%
Sector Avg
-118.5%
(Slower)
Current Ratio
15.39
This Stock
vs
4.55
Sector Avg
+238.4%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OCUL
Ocular Therapeutix, Inc.
|
NEUTRAL | $1.94B | - | -54.9% | -% | $8.91 | |
|
ATRC
AtriCure, Inc.
|
NEUTRAL | $1.94B | - | -6.1% | -5.6% | $39.07 | Compare |
|
MESO
Mesoblast Limited
|
BEARISH | $1.92B | - | -18.2% | -144.3% | $14.7 | Compare |
|
GLPG
Galapagos NV
|
NEUTRAL | $1.92B | 5.16 | 10.4% | 28.8% | $28.56 | Compare |
|
AUPH
Aurinia Pharmaceuticals Inc.
|
NEUTRAL | $1.92B | 26.42 | 20.7% | 29.3% | $14.53 | Compare |
OCUL
Ocular Therapeutix, Inc.
NEUTRAL
Mkt Cap
$1.9B
P/E
-
ROE
-54.9%
Price
$8.91
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-09 | DUGEL PRAVIN U | Chief Executive Officer | Gift | 394,696 | - |
| 2026-02-23 | DUGEL PRAVIN U | Chief Executive Officer | Sale | 20,056 | $166,064 |
| 2026-02-23 | NAYAK SANJAY | Officer | Sale | 1,759 | $14,565 |
| 2026-02-23 | KAISER PETER KAZUO | Officer | Sale | 2,810 | $23,267 |
| 2026-02-23 | HEIER JEFFREY S. | Officer | Sale | 3,057 | $25,312 |
| 2026-02-20 | WAHEED NADIA K. | Officer | Sale | 3,510 | $27,167 |
| 2026-02-20 | LINDSTROM RICHARD L | Director | Purchase | 60,229 | $461,354 |
| 2026-02-12 | NOTMAN DONALD D. JR. | Chief Operating Officer | Sale | 11,446 | $103,472 |
| 2026-02-12 | DUGEL PRAVIN U | Chief Executive Officer | Sale | 124,882 | $1,128,933 |
| 2026-02-12 | NAYAK SANJAY | Officer | Sale | 10,348 | $93,546 |
| 2026-02-12 | WAHEED NADIA K. | Officer | Sale | 7,863 | $71,082 |
| 2026-02-04 | NOTMAN DONALD D. JR. | Chief Operating Officer | Sale | 11,490 | $101,398 |
| 2026-01-21 | ROBINSON DAVID WAYNE | Officer | Stock Award | 136,000 | - |
| 2026-01-02 | NOTMAN DONALD D. JR. | Chief Operating Officer | Stock Award | 79,112 | - |
| 2026-01-02 | NAYAK SANJAY | Officer | Stock Award | 64,900 | - |
DUGEL PRAVIN U
Chief Executive Officer
2026-04-09
394,696 shares
DUGEL PRAVIN U
Chief Executive Officer
2026-02-23
20,056 shares
·
$166,064
NAYAK SANJAY
Officer
2026-02-23
1,759 shares
·
$14,565
KAISER PETER KAZUO
Officer
2026-02-23
2,810 shares
·
$23,267
HEIER JEFFREY S.
Officer
2026-02-23
3,057 shares
·
$25,312
WAHEED NADIA K.
Officer
2026-02-20
3,510 shares
·
$27,167
LINDSTROM RICHARD L
Director
2026-02-20
60,229 shares
·
$461,354
NOTMAN DONALD D. JR.
Chief Operating Officer
2026-02-12
11,446 shares
·
$103,472
DUGEL PRAVIN U
Chief Executive Officer
2026-02-12
124,882 shares
·
$1,128,933
NAYAK SANJAY
Officer
2026-02-12
10,348 shares
·
$93,546
WAHEED NADIA K.
Officer
2026-02-12
7,863 shares
·
$71,082
NOTMAN DONALD D. JR.
Chief Operating Officer
2026-02-04
11,490 shares
·
$101,398
ROBINSON DAVID WAYNE
Officer
2026-01-21
136,000 shares
NOTMAN DONALD D. JR.
Chief Operating Officer
2026-01-02
79,112 shares
NAYAK SANJAY
Officer
2026-01-02
64,900 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
11 analysts
HC Wainwright & Co.
2026-04-13
Buy
Buy
Clear Street
2026-03-03
Buy
Buy
Needham
2026-02-20
Buy
Buy
Chardan Capital
2026-02-18
Buy
Buy
Chardan Capital
2025-12-09
Buy
Buy
Needham
2025-12-08
Buy
Buy
HC Wainwright & Co.
2025-12-08
Buy
Buy
HC Wainwright & Co.
2025-11-25
Buy
Buy
Chardan Capital
2025-11-05
Buy
Buy
TD Cowen
2025-10-30
Buy
Buy
Past News Coverage
Recent headlines mentioning OCUL from our newsroom.
Newest → oldest
No matching news yet.